Heron Therapeutics (HRTX) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
Heron Therapeutics Announces First Quarter 2015 Financial Results and Corporate Progress
May 8, 2015 8:00 AM EDTREDWOOD CITY, Calif.--(BUSINESS WIRE)-- Heron Therapeutics, Inc. (NASDAQ: HRTX), today reported first quarter 2015 financial results and highlighted recent corporate progress.
First Quarter and Recent Corporate Progress:
In April 2015, the Company completed enrollment in MAGIC, its Phase 3 study evaluating the efficacy of SUSTOL® (granisetron injection, extended release) for the prevention of delayed-onset chemotherapy induced nausea and vomiting (CINV) following administration of highly emetogenic chemotherapy (HEC) agents. The study enrolled over 900 patients undergoing treatment for various tumor types at approximately 200 U.S. sites.
In March 2015, the Company disclosed positive... More
